Literature DB >> 9672850

In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes.

Y C Lone1, I Motta, E Mottez, Y Guilloux, A Lim, F Demay, J P Levraud, P Kourilsky, J P Abastado.   

Abstract

We have previously described the production and purification of a murine single-chain, soluble recombinant major histocompatibility complex (MHC) class I molecule (SC-Kd). A similar strategy was devised to produce a recombinant HLA-A2.1 (SC-A2) molecule. The latter was composed of the first three domains of the HLA-A2.1 heavy chain connected to human beta 2-microglobulin through a spacer of 15 amino acids. Immunoaffinity-purified SC-A2 molecules-were correctly folded and biologically functional. They specifically bound HLA-A2-restricted peptides and induced a peptide-specific cytotoxic T lymphocyte (CTL) clone to proliferate and secrete interleukin-2. The ability of murine and human SC-MHC molecules to elicit primary CTLs in vitro was next investigated. When coated in high density onto beads, complexes of antigenic peptide and SC-Kd or SC-A2 molecules efficiently induced a specific primary CTL response in vitro. Furthermore, the structural features of these CTLs were characterized by T cell receptor-beta chain analysis, which revealed rearrangements very similar, if not identical, to those found in CTLs generated by in vivo immunization. Such single-chain, soluble recombinant MHC class I molecules should provide a useful tool in particular for peptide binding assays and for in vitro primary CTL induction to identify immunogenic peptides such as those derived from known tumor-associated antigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672850     DOI: 10.1097/00002371-199807000-00006

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

Review 1.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

2.  Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope.

Authors:  C-H Huang; S Peng; L He; Y-C Tsai; D A K Boyd; T H Hansen; T-C Wu; C-F Hung
Journal:  Gene Ther       Date:  2005-08       Impact factor: 5.250

3.  Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection.

Authors:  Nourredine Himoudi; Jean-Daniel Abraham; Anne Fournillier; Yu Chun Lone; Aurélie Joubert; Anne Op De Beeck; Delphine Freida; François Lemonnier; Marie Paule Kieny; Geneviève Inchauspé
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  The HLA-G*0105N null allele induces cell surface expression of HLA-E molecule and promotes CD94/NKG2A-mediated recognition in JAR choriocarcinoma cell line.

Authors:  Frédéric G Sala; Pierre-Marie Del Moral; Nathalie Pizzato; Florence Legrand-Abravanel; Philippe Le Bouteiller; Françoise Lenfant
Journal:  Immunogenetics       Date:  2004-11-13       Impact factor: 2.846

Review 5.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

6.  Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes.

Authors:  P Savage; P Cowburn; A Clayton; S Man; A McMichael; N Lemoine; A Epenetos; G Ogg
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

7.  Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.

Authors:  G S Ogg; P R Dunbar; V Cerundolo; A J McMichael; N R Lemoine; P Savage
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.